Incyte (INCY) Return on Capital Employed (2011 - 2026)
Incyte (INCY) reported Return on Capital Employed of 28.47% for Q1 2026, up 2396.0% on a YoY basis from 1.14% in Q1 2025, and down 3.62% quarter-over-quarter from 29.54% in Q4 2025.
Incyte (INCY) Return on Capital Employed (2011 - 2026) Analysis & Trends
Incyte has reported Return on Capital Employed for 16 years, with the latest figure at 28.47% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2396.0% year-over-year to 28.47%; the trailing twelve-month figure through Mar 2026 stood at 28.47% (up 2396.0% YoY), and the FY2025 full-year result was 32.33%, up 3096.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 28.47%, down from 29.54% in the prior quarter.
- The five-year high for Return on Capital Employed was 31.25% in Q3 2025, with the low at 1.59% in Q3 2024.
- Historically, Return on Capital Employed has averaged 13.62% across 5 years, with a median of 12.36% in 2024.
- Annual changes were most pronounced in 2024 — Return on Capital Employed slumped 1131 bps — and 2025, when it jumped 3284 bps.
- Incyte's Return on Capital Employed stood at 12.82% in 2022, then dropped by 9 bps to 11.61% in 2023, then tumbled by 85 bps to 1.71% in 2024, then jumped by 1626 bps to 29.54% in 2025, then decreased by 4 bps to 28.47% in 2026.
- The last three Return on Capital Employed figures came in at 28.47% (Q1 2026), 29.54% (Q4 2025), and 31.25% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 28.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.47% |
| Dec 31, 2025 | 29.54% |
| Sep 30, 2025 | 31.25% |
| Jun 30, 2025 | 26.25% |
| Mar 31, 2025 | 4.50% |
| Dec 31, 2024 | 1.71% |
| Sep 30, 2024 | -1.59% |
| Jun 30, 2024 | 0.35% |
| Mar 31, 2024 | 12.36% |
| Dec 31, 2023 | 11.61% |
| Sep 30, 2023 | 9.73% |
| Jun 30, 2023 | 8.74% |
| Mar 31, 2023 | 10.13% |
| Dec 31, 2022 | 12.82% |
| Sep 30, 2022 | 14.07% |
| Jun 30, 2022 | 16.83% |
| Mar 31, 2022 | 14.69% |
| Dec 31, 2021 | 15.78% |
| Sep 30, 2021 | 19.32% |
| Jun 30, 2021 | 13.10% |